Amarin (AMRN)
(Delayed Data from NSDQ)
$0.57 USD
-0.02 (-2.78%)
Updated Sep 25, 2024 03:59 PM ET
After-Market: $0.57 0.00 (0.53%) 6:56 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Brokerage Reports
0 items in cart
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 101 - 120 ( 367 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Battle Didn''t Go as Planned but the War is Far from Over
Provider: Piper Sandler
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Consultant Affirms Judges Were Tough, Remain HOLD Though US Now Priced Out...
Provider: Jefferies & Company
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Color From Appeal Hearing Incrementally Negative For AMRN, In Our View; We Are Staying On The Sidelines
Provider: Stifel Nicolaus Co., Inc.
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa Federal Appeals Decision Expected as Soon 2020, Pushing Forward With European Impetus; PT Under Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Key Paper by REDUCE-IT PI Points to Another Flaw in Ruling vs. Vascepa
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
The Spotlight Is on Vascepa and CV Risk in the Face of COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Healthcare Dial In to Part 3 of Our Omega-3 Call Series Today at 12PM ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Do Not Miss Part 3 - 4 of Our Omega-3 Call Series on May 29 - June 18
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Patent Attorney Perspectives on Vascepa Appeal Opening Brief
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department